175 related articles for article (PubMed ID: 18043252)
21. Development of new drug strategies in infrequent digestive tumors: esophageal, biliary tract, and anal cancers.
Capdevila J; Ramos FJ; Macarulla T; Elez E; Ruiz-Echarri M; Perez-Garcia J; Tabernero J
Curr Opin Oncol; 2009 Jul; 21(4):374-80. PubMed ID: 19412097
[TBL] [Abstract][Full Text] [Related]
22. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
Newton HB
Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
[TBL] [Abstract][Full Text] [Related]
23. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
Crawford J
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
[TBL] [Abstract][Full Text] [Related]
24. Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches.
Harris PJ; Bible KC
Expert Opin Investig Drugs; 2011 Oct; 20(10):1357-75. PubMed ID: 21910667
[TBL] [Abstract][Full Text] [Related]
25. Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways.
Roy V; Perez EA
Breast Cancer Res Treat; 2009 Jul; 116(1):31-8. PubMed ID: 19101790
[TBL] [Abstract][Full Text] [Related]
26. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy.
Fagin JA
J Endocrinol; 2004 Nov; 183(2):249-56. PubMed ID: 15531713
[TBL] [Abstract][Full Text] [Related]
27. EORTC-GU group expert opinion on metastatic renal cell cancer.
de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
[TBL] [Abstract][Full Text] [Related]
28. Clinical development of kinase inhibitors for the treatment of differentiated thyroid cancer.
Ho AL; Sherman E
Clin Adv Hematol Oncol; 2011 Jan; 9(1):32-41. PubMed ID: 21326144
[TBL] [Abstract][Full Text] [Related]
29. Triple-negative breast cancer.
Stockmans G; Deraedt K; Wildiers H; Moerman P; Paridaens R
Curr Opin Oncol; 2008 Nov; 20(6):614-20. PubMed ID: 18841042
[TBL] [Abstract][Full Text] [Related]
30. Individualized therapy of disseminated cancer using malignant melanoma as a model.
Hauschild A; Egberts F; Russo P; Kähler KC
Cancer Metastasis Rev; 2006 Jun; 25(2):253-6. PubMed ID: 16770537
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
Schlumberger MJ; Elisei R; Bastholt L; Wirth LJ; Martins RG; Locati LD; Jarzab B; Pacini F; Daumerie C; Droz JP; Eschenberg MJ; Sun YN; Juan T; Stepan DE; Sherman SI
J Clin Oncol; 2009 Aug; 27(23):3794-801. PubMed ID: 19564535
[TBL] [Abstract][Full Text] [Related]
32. [Current progress and management in molecular targeted therapy for advanced thyroid cancer].
Okamura R; Sugitani I
Gan To Kagaku Ryoho; 2014 Feb; 41(2):148-52. PubMed ID: 24743192
[TBL] [Abstract][Full Text] [Related]
33. Molecular targeted therapies for patients with refractory thyroid cancer.
Chougnet C; Brassard M; Leboulleux S; Baudin E; Schlumberger M
Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):448-55. PubMed ID: 20554167
[TBL] [Abstract][Full Text] [Related]
34. [Targeted therapy in thyroid cancer: Towards a treatment card].
Lkhoyaali S; Benhmida S; Ait Elhaj M; Layachi M; Bensouda Y; Errihani H
Pathol Biol (Paris); 2015 Feb; 63(1):1-6. PubMed ID: 25555494
[TBL] [Abstract][Full Text] [Related]
35. Targeted therapy in thyroid cancer.
Nixon IJ; Shaha AR; Tuttle MR
Curr Opin Otolaryngol Head Neck Surg; 2013 Apr; 21(2):130-4. PubMed ID: 23435040
[TBL] [Abstract][Full Text] [Related]
36. Novel treatment of medullary thyroid cancer.
Sugawara M; Geffner DL; Martinez D; Hershman JM
Curr Opin Endocrinol Diabetes Obes; 2009 Oct; 16(5):367-72. PubMed ID: 19633548
[TBL] [Abstract][Full Text] [Related]
37. Molecular target therapy for gastroenteropancreatic endocrine tumours: biological rationale and clinical perspectives.
Capurso G; Fazio N; Festa S; Panzuto F; De Braud F; Delle Fave G
Crit Rev Oncol Hematol; 2009 Nov; 72(2):110-24. PubMed ID: 19249226
[TBL] [Abstract][Full Text] [Related]
38. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
39. Emerging drugs for esophageal cancer.
Homs MY; Voest EE; Siersema PD
Expert Opin Emerg Drugs; 2009 Jun; 14(2):329-39. PubMed ID: 19453287
[TBL] [Abstract][Full Text] [Related]
40. Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma.
Santarpia L; Ye L; Gagel RF
J Intern Med; 2009 Jul; 266(1):99-113. PubMed ID: 19522829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
